. Author manuscript; available in PMC: 2009 Jul 22.

Published in final edited form as: Nature. 2009 Jan 22;457(7228):426–433. doi: 10.1038/nature07758

Table 2.

Current clinical trials of RNAi-based therapeutics

siRNA	Company	Disease	Stage
Bevasiranib	Acuity Pharmaceuticals	Wet age-related macular degeneration	Phase III
Bevasiranib	Acuity Pharmaceuticals	Diabetic macular oedema	Phase II
Sirna-027	Merck–Sirna Therapeutics	Wet age-related macular degeneration	Phase II
RTP801i-14	Quark Pharmaceuticals, and Silence Therapeutics	Wet age-related macular degeneration	Phase I/IIA
ALN-RSV01	Alnylam Pharmaceuticals	Respiratory syncytial virus infection	Phase II
NUC B1000	Nucleonics	Hepatitis B	Phase I
Anti-tat/rev shRNA	City of Hope National Medical Center, and Benitec	AIDS	Pilot feasibility study
CALAA-01	Calando Pharmaceuticals	Solid tumours	Phase I
TD101	Trans Derm, and the International Pachyonychia Congenita Consortium	Pachyonychia congenita	Phase I